Friday, April 26, 2019

Neustar Research Shows Large Attacks Growing as Multi-Vector Exploits Increasingly Become the Norm

Neustar Security Operations Center (SOC) saw growth at both sides of the attack size spectrum with 77% of attacks using two or more vectors in Q1, 2019

STERLING, Va.-Friday 26 April 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Neustar, Inc., a trusted, neutral provider of real-time information services, today released its Q1, 2019 Cyber Threats and Trends report which highlights new areas of growth in Distributed Denial of Service (DDoS) attacks over the past year.

The report affirms that DDoS attacks continue to be an effective means to distract and confuse security teams while inflicting serious damage to brands.

The report reveals that while volumetric attacks over 50Gbps remain a relatively small segment of the overall threat picture at only 12% of attacks, their frequency has grown enormously when compared to the same period in 2018. The latest attacks morph over the course of the attack using a variety of ports and protocols to locate and exploit vulnerabilities. In Q1, 2019, over 77% of attacks used two or more vectors.

In particular, the trend of targeting subnets and classless inter-domain routing (CIDR) blocks to slow or stop network traffic across the internet is a disruptive DDoS threat, identified in the report. By using DDoS methods aimed completely at subnets, rather than specific IP addresses, an attack is often more difficult to detect and mitigate. These attacks often feature multiple vectors, and will switch between them as they migrate from subnet to subnet.

Neustar handled a mitigation for just such an attack in an around-the-clock collaboration between SOC engineers and a new customer who was quickly onboarded by Neustar after being dropped [during the attack] by their Tier 1 Internet Service Provider (ISP).

“Today’s artificial intelligence and machine learning technologies enable us to identify anomalous traffic and patterns, correlate data across systems, and perform behavioral analytics on users and entities,” said Rodney Joffe, Neustar Senior Vice President, Technologist and Fellow. “But none of these systems function without professionals who know how to deploy them, interpret their data, identify the existence and location of problems, and mitigate them.”

Such immediate personal involvement with expert engineers is a significant benefit in working with an established firm such as Neustar, particularly when under attack. “Neustar’s 10+Tbps of scrubbing capacity and variety of offerings are world class, and we have more power than ever to defend against the range of DDoS attacks,” said Michael Kaczmarek, Neustar Vice President of Security Products. “But it’s important to remember our most powerful defense: people.”

Neustar provides its customers with the resources and assurance that are needed to ensure data and infrastructure is continually protected against any type or size of DDoS attack. Neustar’s DDoS Mitigation Solutions offer the largest dedicated global network with over 10Tbps + of scrubbing capacity in North America, Europe, Asia, South America, Africa, Australia and India.

A complimentary copy of The Neustar Q1’19 Cyber Threats and Trends Report is available here.

About Neustar

Neustar, Inc. is a leading global information services provider driving the connected world forward with responsible identity resolution. As a company built on a foundation of Privacy by Design, Neustar is depended upon by the world’s largest corporations to help grow, guard and guide their businesses with the most complete understanding of how to connect people, places and things. Neustar’s unique, accurate and real-time identity system, continuously corroborated through billions of transactions, empowers critical decisions across our clients’ enterprise needs. More information is available at https://www.home.neustar.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190424005532/en/

Contacts

Sheila S. Blackwell
Sheila.blackwell@team.neustar
301.717.7345


Permalink : https://www.aetoswire.com/news/neustar-research-shows-large-attacks-growing-as-multi-vector-exploits-increasingly-become-the-norm/en

Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia

Submission to EMA follows Biologics Licensing Application submission to U.S. FDA earlier this month


SUMMIT, N.J. & CAMBRIDGE, Mass.-Friday 26 April 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts, require red blood cell (RBC) transfusions and have received or are not eligible for erythropoiesis-stimulating agents, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. Luspatercept is an investigational erythroid maturation agent that regulates late-stage red blood cell maturation.

The safety and efficacy results provided in the application are from the pivotal phase 3 studies MEDALIST and BELIEVE, evaluating the ability of luspatercept to effectively address anemia associated with MDS and beta-thalassemia, respectively.

“As a first-in-class erythroid maturation agent, luspatercept has the potential to become an important therapeutic option for patients with these serious diseases by treating the associated anemia and reducing the burden of transfusions,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “We, along with our partners at Acceleron, now look forward to the regulatory process as we strive to deliver luspatercept to patients in need.”

Luspatercept is an investigational therapy that is not approved for any use in any country.

About Luspatercept

Luspatercept is a first-in-class erythroid maturation agent (EMA) that regulates late-stage red blood cell maturation. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. A phase 3 trial (COMMANDS) in ESA-naïve, lower-risk MDS patients, the BEYOND phase 2 trial in non-transfusion-dependent beta-thalassemia, and a phase 2 trial in myelofibrosis are ongoing. For more information, please visit www.clinicaltrials.gov.

About MEDALIST

MEDALIST is a phase 3, randomized, double blind, placebo-controlled, multi-center study evaluating the safety and efficacy of luspatercept in adults with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS). All patients were RBC transfusion dependent and were either refractory or intolerant to prior erythropoiesis-stimulating agent (ESA) therapy or were ESA naïve with endogenous serum erythropoietin ≥ 200 U/L and had no prior treatment with disease modifying agents. The median age of the patients enrolled in the trial was 71 years in the luspatercept treatment group and 72 years in the placebo group. Median transfusion burden in both treatment arms was 5 RBC units/8 weeks. 229 patients were randomized to receive either luspatercept 1.0 mg/kg (153 patients) or placebo (76 patients) by subcutaneous injection once every 21 days. The study was conducted at 65 sites in 11 countries.

About BELIEVE

BELIEVE is a phase 3, randomized, double blind, placebo-controlled multicenter study comparing luspatercept + best supportive care (BSC) versus placebo + BSC in adults with beta-thalassemia patients who require regular RBC transfusions. The median age of the patients was 30 years in both treatment arms. 336 patients were randomized to receive either luspatercept 1.0 mg/kg (224 patients) or placebo (112 patients) by subcutaneous injection every 21 days for up to 48 weeks. Crossover to the luspatercept treatment groups was allowed after unblinding based on the recommendation of an independent Data Safety Monitoring Committee; patients treated with luspatercept will be followed for up to 3 years. The study was conducted at 65 sites in 15 countries.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com.

Follow Celgene on Social Media: Twitter, Pinterest, LinkedIn, Facebook and YouTube.

About Acceleron

Acceleron is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in Phase 2 development in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease and is conducting a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of, and plans relating to the collaboration between Acceleron and Celgene; the potential of luspatercept as a therapeutic drug; and the benefit of each company’s strategic plans and focus. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would,” “could,” “potential,” “possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs. For example, there can be no guarantee that luspatercept will be successfully developed or complete necessary clinical phases. Forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: results of clinical trials, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; the ability to obtain and maintain requisite regulatory approvals and to enroll patients in planned clinical trials; the ability to obtain, maintain and enforce patent and other intellectual property protection for luspatercept; the ability to maintain key collaborations; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in each company’s public filings with the Securities and Exchange Commission and with respect to Celgene includes risk factors related to the proposed transaction between Bristol-Myers Squibb and Celgene, such as, but not limited to, the risks that: management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; and Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel. Any forward-looking statements contained in this press release speak only as of the date hereof, and neither company has any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Hyperlinks are provided as a convenience and for informational purposes only. Neither Celgene nor Acceleron bears responsibility for the security or content of external websites or websites outside of their respective control.

Contacts

Celgene Corporation
Investors:
+1-908-673-9628
ir@celgene.com
or
Media:
+1-908-673-2275
media@celgene.com

Acceleron Pharma Inc.
Investors:
Todd James, IRC, (617) 649-9393
Vice President, Investor Relations and Corporate Communications
or
Media:
Matt Fearer, (617) 301-9557
Director, Corporate Communications

Permalink : https://www.aetoswire.com/news/celgene-corporation-and-acceleron-pharma-announce-submission-of-luspatercept-marketing-authorization-application-to-the-european-medicines-agency-ema-for-mds-and-beta-thalassemia/en

Fakih IVF Addresses the Barriers Causing Infertility during National Infertility Week

 And emphasizes on adapting a healthy lifestyle to help improve the chances of conceiving



Dubai, United Arab Emirates-Thursday 25 April 2019 [ AETOS Wire ]

Infertility is often a silent struggle. Patients finding it difficult to conceive often experience stress, anxiety, isolation and emotional strain. With National Infertility Awareness week falling between April 21- 27, Fakih IVF plans to raise awareness and reach out to couples battling infertility.

Dr. Michael Fakih, Medical Director of Fakih IVF Fertility Center said it is crucial to understand the reason behind infertility and to be aware about the various treatment options available. “Patients need to educate themselves about the possible alternatives and seek proper medical intervention from experts in the field to better their prospects of starting a family. It’s a trying time for each family and because we understand their situation, we have services designed that personally cater to the needs of each patient that can make their IVF journey a lot easier,” he said.

It is also recommended for infertile patients to follow a healthy lifestyle to improve their chances of conceiving. Men are recommended to incorporate greens and foods rich in antioxidants in their diet, exercise regularly, quit smoking or taking any form of steroids and treat underlying medical conditions like diabetes, infection of the reproductive system or urinary, thyroid disease, celiac disease and anemia.

Female infertile patients are suggested to maintain a healthy diet and weight, limit the intake of caffeine and alcohol, are recommended to work around their cycle and use ovulation tests and are preferably asked to start taking folic acid.

At Fakih IVF Fertility Centre, a variety of services are available to treat infertile patients. “We welcome all individuals seeking advice related to their fertility and also run various online and offline campaigns to educate people about various topics related to infertility. Our specialists offer one-on-one patient education sessions for those who prefer a more confidential setting,” Dr. Fakih said.

Therefore, in support of National Infertility Awareness Week Fakih IVF Dubai is offering a 15 per cent discount on IVF-ICSI packages and free consultation for first time visitors, throughout the month of April.

Contacts

SAHARA Communications

Noor Abdelhafez, Account Executive, +97143298996, +971506946519

n.hafiz@saharapr.com / www.saharagcc.com

Permalink : https://www.aetoswire.com/news/fakih-ivf-addresses-the-barriers-causing-infertility-during-national-infertility-week/en

IDEMIA Will Present Its Q1 2019 Financial Results to Investors on April 29, 2019



PARIS-Thursday 25 April 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- IDEMIA, the world leader in Augmented Identity, today announced that it will present its Q1 2019 financial results to investors on Monday April 29, 2019.

Yann Delabrière (CEO) and Laurent Lemaire (CFO) will be presenting the financial results and taking questions the same day at 3:30 pm CET (2:30 pm London Time / 9:30 am New York Time).

For more information, please refer to our website: https://investors.idemia.com/

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect, travel and vote), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter

Contacts

Press, Hanna Sebbah, idemia@havas.com


Permalink : https://www.aetoswire.com/news/idemia-will-present-its-q1-2019-financial-results-to-investors-on-april-29-2019/en

Project Management Institute, Inc. (PMI) Delivers Full Suite of Certification Exams in Over 5,000 Locations Through Expanded Testing Agreement with Pearson VUE

PHILADELPHIA-Thursday 25 April 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Project Management Institute, Inc. (PMI), the leading not-for-profit professional membership association for the project management profession, and Pearson VUE, a global leader in the computer-based testing industry, have announced an expanded, multi-year agreement that will offer more testing options for candidates looking to earn PMI certifications at all stages of their career. The new agreement will offer candidates access to even more PMI certification tests as well as more flexibility in their testing location options, thanks to Pearson VUE’s global network of testing centers and online proctoring solutions.

Beginning July 1, 2019, seven additional PMI programs, including the Project Management Professional (PMP)® – renowned as the global gold standard for project management professionals – will become available to professionals around the globe through Pearson VUE’s network of more than 5,600 secure test centers, including locations on military bases. Certain exams, like the Agile Certified Professional (PMI-ACP), one of PMI’s fastest-growing certifications, will also be offered via an online proctoring solution that allows test-takers to sit for an exam at their home, school, company, or other suitable testing location. PMI has been offering its associate level certification, the Certified Associate in Project Management (CAPM)® through Pearson VUE’s online remote proctoring capability since 2017.

“At PMI, we are committed to providing opportunities for project management professionals around the world to obtain the certifications necessary to excel and advance their careers,” said Michael DePrisco, vice president, global solutions at Project Management Institute, Inc. “We understand that PMI members are busy working professionals and this expanded partnership will make testing for PMI certifications more accessible by giving candidates more options on where they get certified. By unlocking access to Pearson VUE’s expansive network of testing sites and online proctoring capabilities, we hope to make the test-taking experience more convenient and enhance the overall certification process.”

“Without exception, PMI’s standards for project, program, and portfolio management are the most widely recognized in the profession, and we’re delighted to further serve PMI’s project management community,” said Bob Whelan, president of Pearson Assessments. “With our expanded partnership, we look forward to delivering project management practitioners an all-around better exam experience while helping PMI achieve its strategic vision to advance the project management profession globally through our expansive test delivery channels.”

This most recent agreement adds global delivery of the following PMI certification exams: Project Management Professional (PMP)®, Agile Certified Professional (PMI-ACP)®, Professional in Business Analysis (PMI-PBA)®, Program Management Professional (PgMP)®, Portfolio Management Professional (PfMP)®, Risk Management Professional (PMI-RMP)®, and Scheduling Professional (PMI-SP)®.

About Project Management Institute (PMI)

Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Founded in 1969, PMI delivers value for more than three million professionals working in nearly every country in the world through global advocacy, collaboration, education and research. We advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com creates online global communities that deliver more resources, better tools, larger networks and broader perspectives.

Visit us at www.PMI.org, www.facebook.com/PMInstitute and on Twitter @PMInstitute.

About Pearson VUE

Pearson VUE has been a pioneer in the computer-based testing industry for decades, delivering more than 15 million certification and licensure exams annually in every industry from academia and admissions to IT and healthcare. We are the global leaders in developing and delivering high-stakes exams via the world's most comprehensive network of nearly 20,000 highly secure test centers in 180 countries. Our leadership in the assessment industry is a result of our collaborative partnerships with a broad range of clients, from leading technology firms to government and regulatory agencies. For more information, please visit PearsonVUE.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005149/en/

Contacts
Mary Ortega
610-356-4600 x7030
Mary.Ortega@pmi.org

Nancy Jerdee
952-681-3798
nancy.jerdee@pearson.com


https://www.aetoswire.com/news/project-management-institute-inc-pmi-delivers-full-suite-of-certification-exams-in-over-5000-locations-through-expanded-testing-agreement-with-pearson-vue/en

Thursday, April 25, 2019

Aventri Introduces Uber Vouchers to Deliver New Transportation Options

NORWALK, Conn.-Thursday 25 April 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Event management software (EMS) leader Aventri today announces a new partnership with Uber for Business. Aventri is the first EMS provider to launch a partnership with Uber for Business to offer customers the opportunity to utilize Uber Vouchers. Uber Vouchers’ web-based tool allows event organizers to provide VIP treatment to attendees with stress-free, reliable transportation to and from events.

“We’re always looking for new partners to help our customers streamline events and add value,” said Brad Langley, vice president of channel and partner management for Aventri. “Uber for Business fits the bill. Using Uber Vouchers, organizers spend less time arranging logistics for moving groups, and their guests can come and go at a time that’s convenient for them.”

Using Uber Vouchers, organizers can enhance the journey for themselves and their guests. Some benefits include:

    Customized Control: Organizers can easily create and manage campaigns online by setting parameters for pickup, drop-off, timeframe and ride costs.
    Smarter Planning: Companies are better able to predict and control transportation costs. Organizers only pay for Vouchers their attendees redeem.
    Personalized Experience: Attendees receive a more personalized and memorable travel experience with the ability to arrange the rides they want, when they want.

“We’re delighted to partner with Aventri,” said Neal Watterson, Head of Guest Products and Services, Uber for Business. “Our collaboration provides a new way to simplify events with reliable, well-priced transportation. We are excited about how Uber Vouchers offers a simple and easily scalable way for business to connect with and serve their customers.”

As part of this partnership, the first to take advantage of the new Uber Voucher program were the Aventri global sales and marketing team at the company’s annual revenue kickoff this past February. Parameters were set by Aventri’s event marketing team, allowing attendee pickups and drop-offs from nearby airports to the hotel during the three-day event.

“Everyone has an Uber app, so the vouchers were super-easy to use,” said Roni Romo, event coordinator at Aventri. “I could stay focused on the meeting without having to spend time arranging transportation logistics.”

Uber Vouchers are available today for Aventri customers by signing up through their partner program. To learn more contact Aventri at sales@aventri.com.

“To read the full release, visit

https://www.aventri.com/press-release/aventri-introduces-uber-vouchers-to-deliver-new-transportation-options?hs_preview=bgiTRAqK-9036337378“

Contacts

Kayla Starta, 412-780-7439
Kayla@fifthavenuebrands.com

Permalink : https://www.aetoswire.com/news/aventri-introduces-uber-vouchers-to-deliver-new-transportation-options/en

SugarCRM Announces Game-Changing Product Enhancements to Accelerate Growth, Improve Business Performance and Deliver Exceptional Customer Experiences

New Optimization Features Empower Customers to Process Up to 70% More Sales and Services Transactions

CUPERTINO, Calif.-Thursday 25 April 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- SugarCRM Inc.®, the company that helps organizations build better business relationships, today announced several new platform capabilities to help companies to accelerate their business growth. These new capabilities will enable them to resolve customer issues quickly, collaborate more effectively, make faster and more informed decisions about their customers, eliminate time-consuming manual processes, expand real-time mobile access to critical customer information – and do all of this on the new, blazing-fast Sugar 9 platform.

“With these significant enhancements, our customers can now collaborate and communicate more effectively, know more about their customers to quickly make better decisions and confidently transact more business with faster quotes, more automation and rock-solid SOC 2 compliance. Most importantly, we have boosted system performance to new heights, enabling customers to process up to 70% more transactions without investing in new hardware,” says Rich Green, chief technology officer and chief products officer at SugarCRM.

Empowering customers to accelerate sales from first call to go-live is at the heart of the new Sugar 9 release. “As a business accelerator and innovator, we have a mandate to consistently exceed our customers’ expectations and to thrill them with rapid delivery of new products and capabilities, feature enhancements and performance improvements,” said Green. “We’ve upped our game big time in Sugar 9, anchoring every new capability on acceleration and demonstrating our commitment to evolving and enhancing the user-experience.”

New enhancements to help customers collaborate more, know more, do more, sell more, protect more and go faster include:

    Collaborate more: New email and comments log features enable customer service representatives to collaborate more effectively, resolve customer issues faster and increase customer satisfaction by providing a more unified and consistent service experience.
    Know more: With more than 110 new out-of-the-box reports, more than 60 new chart visualizations and advanced reporting capabilities, customers now can harness the data in Sugar to make better and more informed decisions and optimize their sales and support operations.
    Do more: Workflow automation has been taken to a new level with advanced capabilities in the new SugarBPMTM. Customers now can build new process automations faster and more reliably, automate workflows to ensure time-sensitive deals are processed more quickly and eliminate tedious manual steps to focus their teams on revenue-growth activities.
    Sell more: To make it faster and easier for customers to sell more, Sugar 9 enables them to create fully customized and personalized quotes, quickly add most frequently quoted line items using the Product Catalog Quickpicks Dashlet and access all of this on mobile devices.
    Protect more: To help protect customers, the company has bolstered its security organizational processes and evidence gathering capabilities. As a result, SugarCRM has successfully completed a SOC 2 Type 2 audit, providing third-party validation of the company’s commitment to protecting customers and customer information.
    Go faster: New optimizations improve performance by 7x, making Sugar 9 one of the fastest solutions on the market today. Customers now can process up to 70% more transactions using the same hardware, giving them a competitive edge to close business faster, win more customers and achieve business growth objectives.

To learn more about Sugar 9, view this highlights video featuring Zac Sprackett, senior vice president of product management for SugarCRM.

About SugarCRM

SugarCRM enables businesses to create extraordinary customer relationships with the most empowering, adaptable and affordable customer relationship management (CRM) solution on the market. Unlike traditional CRM solutions that focus primarily on management and reporting, Sugar empowers the individual, coordinating the actions of customer-facing employees and equipping them with the right information at the right time to transform the customer experience.

Based in Silicon Valley, SugarCRM is backed by Accel-KKR. More than 2 million individuals in over 120 countries rely on SugarCRM.

To learn more visit http://www.sugarcrm.com or follow @SugarCRM.

NOTE: SugarCRM and the SugarCRM logo are registered trademarks of SugarCRM Inc. Third-party trademarks mentioned are the property of their respective owners.

Contacts

Angela Connor
Change Agent Communications
angela@changeagentcommunications.com
919-635-8527

Permalink : https://www.aetoswire.com/news/sugarcrm-announces-game-changing-product-enhancements-to-accelerate-growth-improve-business-performance-and-deliver-exceptional-customer-experiences/en